Close Menu

NEW YORK – Abbott reported Wednesday that its 2020 third quarter Diagnostics business revenues rose 38 percent year over year, due to sales of its COVID-19 portfolio.

For the three months ended Sept. 30, the Abbott Park, Illinois-based firm reported overall revenues of $8.85 billion, up nearly 10 percent on a reported basis from $8.08 billion a year ago and beating the consensus Wall Street estimate of $8.51 billion. The firm said that its organic sales, excluding the impact of foreign exchange, grew 11 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.